Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer

World Journal of Gastroenterology

Volumn 20, Issue 7, 2014, Pages 1650-1656

  Kwee, Robert Michael ^a   Kwee, Thomas Christian ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Chemotherapy; Gastric cancer; Imaging; Neoadjuvant therapy; Response

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ANATOMICAL IMAGING; ARTICLE; BIBLIOGRAPHIC DATABASE; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; MOLECULAR IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; STOMACH CANCER; SURVIVAL; TREATMENT RESPONSE; ADJUVANT THERAPY; CHEMISTRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DIFFUSION MAGNETIC RESONANCE IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84894259536     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i7.1650     Document Type: Article

References (41)

1. World Health Organization. GLOBOCAN 2008. Available from: URL: http://globocan.iarc.fr/factsheets/populations/ factsheet.asp?uno=900
2. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008; 9: 279-287 [PMID: 18308253 DOI: 10.1016/S1470-2045(08)70072-X]
3. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol 2010; 16: 5621-5628 [PMID: 21105197 DOI: 10.3748/wjg. v17.i40.4542]
4. Knight G, Earle CC, Cosby R, Coburn N, Youssef Y, Malthaner R, Wong RK. Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer 2013; 16: 28-40 [PMID: 22467061 DOI: 10.1007/s10120-012-0148-3]
5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20 [PMID: 16822992 DOI: 10.1056/NEJMoa055531]
6. Kurokawa Y, Shibata T, Sasako M, Sano T, Tsuburaya A, Iwasaki Y, Fukuda H. Validity of response assessment criteria in neoadjuvant chemotherapy for gastric cancer (JCOG0507-A). Gastric Cancer 2013 Sep 3; Epub ahead of print [PMID: 23999869 DOI: 10.1007/s10120-013-0294-2]
7. Liu K, Li G, Fan C, Zhou C, Li J. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy. Acta Radiol 2012; 53: 127-134 [PMID: 22156007 DOI: 10.1258/ar.2011.110273]
8. Lee SM, Kim SH, Lee JM, Im SA, Bang YJ, Kim WH, Kim MA, Yang HK, Lee HJ, Kang WJ, Han JK, Choi BI. Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdom Imaging 2009; 34: 430-440 [PMID: 18546037 DOI: 10.1007/s00261-008-9420-8]
9. Guo T, Yao F, Yang AM, Li XY, Zhong DR, Wu DS, Wu X, Lu XH. Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. Asia Pac J Clin Oncol 2012 Dec 21; Epub ahead of print [PMID: 23279745 DOI: 10.1111/ ajco.12045]
10. Ang J, Hu L, Huang PT, Wu JX, Huang LN, Cao CH, Zheng YX, Chen L. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol 2012; 18: 7026-7032 [PMID: 23323004 DOI: 10.3748/wjg.v18.i47.7026]
11. Park SR, Lee JS, Kim CG, Kim HK, Kook MC, Kim YW, Ryu KW, Lee JH, Bae JM, Choi IJ. Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer 2008; 112: 2368-2376 [PMID: 18404697. DOI: 10.1002/cncr.23483]
12. D'Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, Ricci R. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol 2006; 32: 1105-1109 [PMID: 16930932 DOI: 10.1016/ j.ejso.2006.07.009]
13. Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol 2012; 19: 2119-2127 [PMID: 22395980. DOI: 10.1245/s10434-012-2254-1]
14. Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K, Siewert JR, Ott K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer 2013 Sep 1; Epub ahead of print [PMID: 23996162 DOI: 10.1007/s10120-013-0296-0]
15. Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21: 4604-4610 [PMID: 14673049 DOI: 10.1200/JCO.2003.06.574]
16. Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 2008; 14: 2012-2018 [PMID: 18381939. DOI: 10.1158/1078-0432.CCR-07-0934]
17. Vallböhmer D, Hölscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R, Mönig SP. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 2010; 102: 135-140 [PMID: 20648583 DOI: 10.1002/jso.21592]
18. Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, Zum Büschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 2011; 18: 3316-3323 [PMID: 21537865 DOI: 10.1245/s10434-011-1743-y]
19. Response evaluation criteria in solid tumors. Available from: URL: http://www.recist.com/
20. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma--2nd English edition--response assessment of chemotherapy and radiotherapy for gastric carcinoma: clinical criteria. Gastric Cancer 2001; 4: 1-8 [PMID: 11706621. DOI: 10.1007/s101200100009]
21. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG, Gronchi A. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy. Cancer 2012; 118: 5857-5866 [PMID: 22605504 DOI: 10.1002/cncr.27624]
22. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686 [PMID: 8194005 DOI: 10.1002/1097-0142]
23. American Joint Committee on Cancer. Greene FL, Page DL, Fleming ID, editors. Stomach. AJCC Cancer Staging Manual. 6th edition. New York: Springer, 2002: 99-103
24. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003; 98: 1521-1530 [PMID: 14508841. DOI: 10.1002/cncr.11660]
25. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, Schwaiger M, Fink U. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003; 30: 288-295 [PMID: 12552348 DOI: 10.1007/s00259-002-1029-5]
26. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D, Souvatzoglou M, Becker K, Schuster T, Wester HJ, Siewert JR, Schwaiger M, Krause BJ. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. J Nucl Med 2007; 48: 1945-1950 [PMID: 18006614 DOI: 10.2967/jnumed.107.044867]
27. Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A. Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 2013; 40: 290-301 [PMID: 23151913 DOI: 10.1007/s00259-012-2280-z]
28. Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008; 13 Suppl 2: 19-21 [PMID: 18434634 DOI: 10.1634/theoncologist.13-S2-19]
29. Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progressionfree survival and time to progression as end points of drug efficacy. Cancer J 2009; 15: 395-400 [PMID: 19826359 DOI: 10.1097/PPO.0b013e3181be231d]
30. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308 [PMID: 10077040]
31. Becker K, Reim D, Novotny A, Zum Büschenfelde CM, Engel J, Friess H, Höfler H, Langer R. Proposal for a multifactorial prognostic score that accurately classifies 3 groups of gastric carcinoma patients with different outcomes after neoadjuvant chemotherapy and surgery. Ann Surg 2012; 256: 1002-1007 [PMID: 22968067 DOI: 10.1097/ SLA.0b013e318262a591]
32. Thoeny HC, Ross BD. Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging 2010; 32: 2-16 [PMID: 20575076 DOI: 10.1002/ jmri.22167]
33. Shinya S, Sasaki T, Nakagawa Y, Guiquing Z, Yamamoto F, Yamashita Y. The usefulness of diffusion-weighted imaging (DWI) for the detection of gastric cancer. Hepatogastroenterology 2007; 54: 1378-1381 [PMID: 17708258]
34. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS. Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. J Nucl Med 2013; 54: 936-943 [PMID: 23578997 DOI: 10.2967/jnumed.112.110239]
35. An JY, Kim HI, Cheong JH, Hyung WJ, Kim CB, Noh SH. Pathologic and oncologic outcomes in locally advanced gastric cancer with neoadjuvant chemotherapy or chemoradiotherapy. Yonsei Med J 2013; 54: 888-894 [PMID: 23709422 DOI: 10.3349/ymj.2013.54.4.888]
36. Wang LB, Teng RY, Jiang ZN, Hu WX, Dong MJ, Yuan XM, Chen WJ, Jin M, Shen JG. Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. J Surg Oncol 2012; 105: 293-296 [PMID: 21882201 DOI: 10.1002/jso.22085]
37. Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Müller M, Lordick F, Fink U, Rüdiger Siewert J, Höfler H, Keller G. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 2005; 11: 3025-3031 [PMID: 15837757 DOI: 10.1158/1078-0432.CCR-04-1605]
38. Liu K, Qian T, Tang L, Wang J, Yang H, Ren J. Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World J Surg Oncol 2012; 10: 225 [PMID: 23107361 DOI: 10.1186/1477-7819-10-225]
39. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, Tan SH, Wu J, Lee MH, Ooi CH, Rha SY, Wong WK, Boussioutas A, Yeoh KG, So J, Yong WP, Tsuburaya A, Grabsch H, Toh HC, Rozen S, Cheong JH, Noh SH, Wan WK, Ajani JA, Lee JS, Tellez MS, Tan P. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011; 141: 476-85, 485. e1-11 [PMID: 21684283 DOI: 10.1053/ j.gastro.2011.04.042]
40. Han Y, Cai H, Ma L, Ding Y, Tan X, Chang W, Guan W, Liu Y, Shen Q, Yu Y, Zhang H, Cao G. Expression of orphan nuclear receptor NR4A2 in gastric cancer cells confers chemoresistance and predicts an unfavorable postoperative survival of gastric cancer patients with chemotherapy. Cancer 2013; 119: 3436-3445 [PMID: 23821160 DOI: 10.1002/cncr.28228]
41. Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S. Biomarkers of response to therapy in oesophago-gastric cancer. Gut 2009; 58: 127-143 [PMID: 19091831. DOI: 10.1111/j.1365-2559.2009.03404.x]